In-Vitro Diagnostics Market Analysis to 2017 - Major Competitors in the Market Covered
DUBLIN, July 8, 2013 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/3tj9r6/invitro) has announced the addition of the "In-Vitro Diagnostics Market Analysis to 2017" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The global in-vitro diagnostics (IVD) market is going through a very exciting phase, offering immense opportunities for players involved in the business. The market, which on one hand, is struggling to maintain a foothold in the unstable economy of Europe is growing astoundingly at a high double-digit growth rate in emerging economies of India, China, and Brazil.
This latest research study, In-Vitro Diagnostics Market Analysis to 2017, identifies market dynamics in various important regions to highlight the areas offering promising possibilities for companies to boost their growth. The market, which stood at US$ 52.4 Billion in 2012, is expected to grow at a CAGR of 7% during 2012-2017.
In the report, the IVD market has been studied on three distinct levels: Regional, Clinical and Player level. For regional analysis, key IVD markets that together constitute around 95% of the global market, have been profiled. Further, the market has been divided into eight distinct clinical segments and their current and future outlook to 2017 has been analyzed. Through this, our analysts have conducted a thorough opportunity assessment in various clinical segments and highlighted the clinical segments that offer the maximum opportunity for growth in each region.
Revenue generated from each clinical segment to recognize key segments that offer very high growth rates have also been analyzed. The study further delves into the business dynamics of major players in the industry that together form more than 70% of the global IVD market. To provide a thorough understanding of the Company's business model, Company's current and historical financials have been analyzed. Also, the Company's revenue from IVD has been depicted with a further breakup by clinical segment. The study also portrays each Company's strengths and weaknesses that will help the reader to better position its company vis-à-vis competition.
- Abbott Laboratories
- Alere, Inc.
- Becton Dickinson
- Bayer HealthCare
- Beckman Coulter
- Johnson and Johnson
- Life Technologies Corporation
- Medtronic, Inc.
- Qiagen NV
- Roche Holding Ltd
- Sysmex Corporation
- Siemens HealthCare
- Thermo Fisher Scientific
For more information visit http://www.researchandmarkets.com/research/3tj9r6/invitro
SOURCE Research and Markets